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The ideal approach for the treatment of atrial ﬁbrillation (AF) is
rhythm control, but this is sometimes very hard to accomplish [1]. For
such procedures, complete isolation of all pulmonary veins (PVs) is cur-
rently widely accepted as the best endpoint. Pokushalov and colleagues
[2] recently reported that renal sympathetic denervation (RSD) reduces
AF recurrences when combined with pulmonary vein isolation (PVI).
RSD consists of a recent strategy using percutaneous catheter-based
delivery of radiofrequency (RF) energy to interject the sympathetic
innervation of the kidneys, and PVI is a well established ablation tech-
nique used to treat paroxysmal AF. RSD procedure exposed no severe
vascular or renal complications in the long term (up to 36 months).
Our group believes that RSD can reduce AF recurrence in patients with
chronic kidney disease (CKD) by modulation of the sympathetic hyper-
activity present in this disease. The goal of this prospective study was
to compare the impact of PVI in controlled hypertensive patients with
paroxysmal AFwith andwithout CKD to PVI associatedwith RSD in con-
trolled hypertensive patients with paroxysmal AF and moderate CKD.
This prospective, longitudinal study involved 145 patients with
controlled hypertension and CKD, all of them having a history of symp-
tomatic paroxysmal AF (PAF). The study was piloted in agreement with
the Helsinki declaration and approved by the ethics committee of our
institution. All patients signed the informed consent term before inclu-
sion. This studywas conducted at theHospital e Clínica São Gonçalo, Rio
de Janeiro, Brazil. Patients were recruited from January 2012 till January
2015 from the Arrhythmias and Artiﬁcial Cardiac Pacing Service of the
same hospital. Enrolled patients met the following criteria: (i) mean
24-h systolic ambulatory blood pressure measurement (ABPM) of
≥100 and b130 mm Hg, (ii) essential hypertension for N1 year, (iii) a
physically normal heart with an ejection fraction of N50% as measured
by echocardiography (Simpson's method), (iv) PAF (deﬁned as AF
episodes lasting b7 days with spontaneous termination) registered on
ECG or 24-h Holter monitoring, (v) aged 18 to 80 years, (vi) estimated
glomerular ﬁltration rate (eGFR) of N15 mL/min/1.73 m2, calculated
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation6 (patients with eGFR N60 mL/min/1.73 m2 were also required
to have microalbuminuria), and (vii) the capacity to read, comprehend
and sign the informed consent form, and attend the study. Patients withhttp://dx.doi.org/10.1016/j.ijcme.2016.09.002
2214-7624/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access articlany of the following were excluded: (i) pregnancy; (ii) valvular disease
with signiﬁcant adverse sequelae; (iii) unstable angina, myocardial
infarction, transient ischemic attack or stroke within the preceding
six months; (iv) renovascular abnormalities; (v) psychiatric disease;
(vi) allergy to ionic contrast medium; (vii) the inability to be monitored
clinically after the procedure; (viii) a known addiction to alcohol or
drugs that affects the intellect; (ix) a serious health condition that, in
the investigator's opinion, may have adversely affected the safety and/or
efﬁcacy of the participant or the study (e.g., abdominal aortic aneurysm,
clinically signiﬁcant peripheral vascular disease, diseases that might
have caused bleeding due to thrombocytopenia, hemophilia, or signiﬁ-
cant anemia); (x) congestive heart failure (symptoms of functional class
II to IV heart failure on the New York Heart Association scale); (xi) a pre-
vious AF ablation procedure; (xii) treatment with amiodarone.
The subjects were divided into two groups according to their KDIGO
CKD status, and procedures performed: CKD patients underwent PVI
(n = 96), and CKD patients underwent PVI + RSD (n = 49). All of
them were followed at least 6 months to assess maintenance of sinus
rhythm, to monitor variations in blood pressure and renal function.
The primary endpoint of this studywas a 30-s recurrence of AF recorded
by the 24-hour-Holter monitoring. The blanking period (the ﬁrst
3 months after ablation) was excluded from the analysis [3], and the
24-hour-Holter monitoring was evaluated at baseline and quarterly
after the performance of procedures forward. The secondary endpoints
were an evaluation of mean 24-h ABPM, eGFR (CKD-EPI) [4] and albu-
minuria at baseline and 6 months after the procedures. Additionally,
in the subjects underwent RSD safety was evaluated by a renal arterial
duplex scan at baseline and 6 months after this procedure.
The AF ablation procedure has been described in detail previously
[5]. All patients underwent complete PVI using a three-dimensional
mapping system (EnSite Velocity; St. Jude Medical) without additional
ablation lesion sets or lines. Patients still in AF at the end of the proce-
dure were converted to sinus rhythm by cardioversion.
The RSD procedure has been described in detail previously [6]. The
patients remained hospitalized in theward for 24 h after the procedure.
The results are expressed as a mean and standard deviation for
normally distributed data and asmedianwith interquartile range other-
wise. Comparisons between two-paired values were performed with
the paired t-test in cases of a Gaussian distribution and by theWilcoxon
test otherwise. For normality of distribution, D'Agostino-Pearson test
was used. Comparisons between more than two-paired values were
made by repeated-measures analysis of variance or by Kruskal–Wallis
analysis of variance as appropriate, complemented by the post-hoc
Tukey test. Categorical variables were compared with Fisher's exact
test. A two-tailed P-value b0.05 was used as a criterion for statistical
signiﬁcance. Correlations between two variables were performed by
Pearson's chi-square test in case of a Gaussian distribution and with
the Spearman correlation test otherwise. Kaplan–Meier analysis was
performed to determine the probability of success, estimated as the per-
centage of AF freedom. Differences in arrhythmia-free survival were
assessed with the log-rank test. Cox regression analysis was applied toe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
General features of patients at baseline.
Parameters CKD CKD Overall
P-value
PVI PVI + RSD
N 96 49 —
Age (years) 59 ± 15 63 ± 12 0.1075
Body mass index, kg/m2 26.5 ± 5.8 24.8 ± 9.6 0.1868
Male sex (%) 65 (68%) 30 (61%) 0.4641
White ethnicity (%) 59 (61%) 28 (57%) 0.7204
Paroxysmal AF 96 (100%) 49 (100%) —
Hypertension 96 (100%) 49 (100%) —
Type 2 diabetes mellitus 36 (38%) 17 (35%) 0.8557
Hyperlipidemia 50 (52%) 32 (65%) 0.1574
Chronic kidney disease
Stage 2 46 (48%) 18 (37%) 0.2199
Stage 3 21 (22%) 10 (20%) N0.9999
Stage 4 29 (30%) 21 (43%) 0.1429
Creatinine, mg/dL 1.50 ± 0.12 1.54 ± 0.15 0.0838
eGFR, mL/min/1.73 m2 50.1 ± 5.4 48.3 ± 7.5 0.0996
Albumin:creatinine ratio, mg/g 93 ± 16 98 ± 19 0.0974
Antihypertensive 2.4 ± 0.5 2.2 ± 0.9 0.0874
ACE-inhibitors/ARB 96 (100%) 39 (100%) —
Diuretics 68 (71%) 33 (67%) 0.7048
DHP Ca++ channel blockers 31 (32%) 18 (37%) 0.7108
β-blockers 50 (52%) 23 (47%) 0.6011
Mean 24-hour ABPM, mm Hg
Systolic 119 ± 8 122 ± 15 0.1180
Diastolic 79 ± 8 78 ± 13 0.5684
24-Hour-Holter monitoring
Average heart rate, bpm 75 ± 10 72 ± 17 0.2052
Echocardiographic parameters
Indexed left atrial volume (mL/m2) 40.0 ± 8.2 39.8 ± 9.4 0.8951
IST (mm) 9.2 ± 2.4 9.0 ± 2.3 0.6311
LVPWT (mm) 9.3 ± 1.5 9.5 ± 1.8 0.4796
LVEF, Simpson (%) 66.5 ± 10.0 65.8 ± 12.8 0.7180
LVEDD (mm) 46.2 ± 5.1 47.0 ± 4.3 0.3487
LVESD (mm) 31.9 ± 8.0 31.0 ± 6.9 0.5038
LV mass index (g/m2) 95.4 ± 18.5 94.3 ± 19.4 0.7395
Values are expressed as Mean ± SD; ABPM, ambulatory blood pressure measurements;
ACE, angiotensin-converting enzyme; AF, atrial ﬁbrillation; ARB, angiotensin receptor
blocker; CKD, chronic kidney disease; DHP, dihydropyridine; eGFR, estimated glomerular
ﬁltration rate; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; LVEF,
left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVPWT,
left ventricular posteriorwall thickness; PVI, pulmonary veins isolation; RSD, renal sympa-
thetic denervation.
Table 3
Hazard ratio for AF recurrence between the various stages of CKD evaluated by Log-rank
test.
AF recurrence Hazard ratio 95% conﬁdence interval P-value
PVI
CKD 4 vs. CKD 3 1.031 0.589–1.806 0.9044
CKD 4 vs. CKD 2 8.571 4.199–17.490 b0.0001
CKD 3 vs. CKD 2 7.830 3.344–18.340 b0.0001
PVI + RSD
CKD 4 vs. CKD 3 2.702 1.148–6.361 0.0212
CKD 4 vs. CKD 2 13.620 4.698–39.500 b0.0001
CKD 3 vs. CKD 2 18.140 3.313–99.360 0.0008
PVI vs. PVI + RSD
CKD 4 2.282 1.261–4.128 0.0039
CKD 3 5.564 2.564–12.070 b0.0001
CKD 2 4.309 1.011–18.370 0.0483
AF, atrial ﬁbrillation; CKD, chronic kidney disease; PVI, pulmonary veins isolation; RSD,
renal sympathetic denervation.
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formed using the program Graphpad Prism v 7.0 (Graphpad Software,
La Jolla, CA, USA).
The general features of the groups of patients are listed in Table 1.
Themean follow-upperiod for the236patientswas22.4±12.1months.
No patient developed procedural complications related to PVI or RSD.
Real-time renal artery images were performed at the end of the proce-
dure to evaluate acute eventual structural changes regarding the
RSD. Six months after the procedure, all patients in the RSD group
underwent a Doppler scan of the renal arteries and showed no evidenceTable 2
Effects on blood pressure, heart rate and renal function during the follow-up period.
Parameters CKD (n = 96) CKD (n = 49
PVI PVI + RSD
Baseline 6th month Baseline
Mean systolic 24-hour ABPM, mm Hg 119 ± 8 120 ± 10 122 ± 15
Mean diastolic 24-hour ABPM, mm Hg 79 ± 8 79 ± 5 78 ± 13
Average HR 24-hour-Holter, bpm 75 ± 10 73 ± 14 72 ± 17
Creatinine, mg/dL 1.50 ± 0.12* 1.60 ± 0.10 1.54 ± 0.15*
eGFR, mL/min/1.73 m2 50.1 ± 5.4* 46.0 ± 5.0 48.3 ± 7.5*
ACR, mg/g 93.0 ± 16.0 97.2 ± 22.5 98.0 ± 19.0*
Values presented asMean± SD. ABPM, ambulatory blood pressuremeasurements; ACR, album
HR, heart rate; PVI, pulmonary veins isolation; RSD, renal sympathetic denervation. *P b 0.000of stenosis or ﬂow limitation compared to the same exam at baseline.
No signiﬁcant change was observed on the mean 24-h ABPM and
average heart rate 24-hour-Holter monitoring from baseline to
6 months within the same group. Nor has there been signiﬁcant
differences between the groups at the same time points. The effects
of PVI alone or PVI + RSD on the creatinine concentration, eGFR,
and albumin:creatinine ratio during the ﬁrst 6-month follow-up
are shown in Table 2.
During a mean follow-up period of 19.3 ± 10.9 months, AF recur-
rence was higher in CKD patients underwent PVI than in those submit-
ted to PVI + RSD, hazard ratio [HR], 95% conﬁdence interval [CI] and
P value by Log-rank test, are showed at Table 3. There was difference
related to AF reappearance in the comparison between patients with
CKD submitted to PVI and PVI + RSD at stages of CKD 2, 3 and 4 by
Log-rank test (P b 0.0001), Fig. 1.
We believe that during follow-up, AF recurrence was higher in CKD
patients who underwent PVI than in those with CKD who underwent
PVI + RSD, because of the greatest sympathetic hyperactivity inherent
to advanced CKD stages, suggesting that RSD can suppress sympathetic
overactivity and the associated arrhythmogenic foci. Although our data
show an independent contribution of RSD to reduce AF recurrence
in patients with controlled hypertension and CKD, our patient cohort
was small, which could be seen as a limitation. To our knowledge,
however, the present series is the ﬁrst to address the efﬁcacy of percu-
taneous renal artery denervation in patients with concurrently con-
trolled hypertension, CKD, and AF.
The presence of AF hampersmeasurement of LV ejection fraction be-
cause of tachycardia and beat-to-beat (i.e., R-to-R) LV ﬁlling variability.
Ourmeasurements could have been less precise becausewe did not use
a three-dimensional single-beat ultrasound system. In addition, the use
of Doppler echocardiography to assess damage in the renal arteries





baseline vs. 6th month
6th month
117 ± 13 0.1180 0.3049 0.11951
76 ± 9 0.5684 0.0727 0.0611
70 ± 18 0.2052 0.6137 0.1232
1.30 ± 0.14 0.0838 b0.0001 b0.0001
56.3 ± 6.8 0.0996 b0.0001 b0.0001
62.3 ± 21.2 0.0974 b0.0001 b0.0001
in:creatinine ratio; CKD, chronic kidney disease; eGFR, estimated glomerularﬁltration rate;
1 CKD patients underwent PVI + RSD at baseline vs. 6th month.
Fig. 1. Kaplan–Meier curves depicting recurrences of paroxysmal atrial ﬁbrillation (AF)
following pulmonary vein isolation (PVI) alone or combined with renal sympathetic
denervation (RSD) in chronic kidney disease (CKD) patients.
14 Letter to the Editordue to the RF applications were excluded by angiography performed
at the end of the procedure. Any other method, such as magnetic
resonance angiography, computed tomographic angiography or further
angiography of the renal arteries, could expose patients to additional
undesirable toxic insults. Carbon dioxide angiography is not available
at our institution.
More precise methods of eGFR assessment, such as cystatin C
or iothalamate measurement, should be used in future studies to
further evaluate our ﬁndings concerning the effects of RSD on the
eGFR, especially considering that only one serum creatinine mea-
surement was performed at each time point of the study. The neuro-
muscular sympathetic activity could also be measured, which would
contribute greatly to the assessment of the degree of sympathetic
blockade.
PVI + RSD are safe and appear to be superior to PVI in the treatment
of paroxysmal AF in CKD patients. Although encouraging, our data are
preliminary and need long-term validation in a large population.
PVI + RSD are a potential tool for incorporation into future clinical
practice.
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